The Irish Prostate Cancer Outcomes Research (IPCOR) group aims to enhance prostate cancer care, improve patient experiences and maximise quality of life for men with prostate cancer. A fundamental part of the research is the establishment of a national prostate cancer registry which is made up of high quality clinical data for all men newly diagnosed with prostate cancer in Ireland. The purpose of the IPCOR registry is to monitor patterns and quality of care and provide valuable information back to hospitals, clinicians and patients. It will provide a world-class research tool to better understand and manage prostate cancer disease in Ireland.
IPCOR is funded by the Irish Cancer Society and Movember and has the support of many clinicians treating prostate cancer patients in Ireland who specialise in urology, medical oncology and radiation oncology. The National Cancer Registry will play a key role in this collaborative research partnership which also includes the National Cancer Control Programme, the HRB Clinical Research Facility in Galway and Molecular Medicine Ireland. Led by the principle investigator, Mr David Galvin (a uro-oncologist surgeon in the Mater Misericordiae hospital in Dublin) the data collection is being carried out by IPCOR research officers who are employed by the National Cancer Registry.
Patients with a new diagnosis of prostate cancer are registered onto the database and if appropriate they will be contacted via letter to take part in a patient reported outcomes survey. Men will receive and fill in quality of life questionnaires once a year. This information will be added to the database. The patients will be followed up for a period of 5 years to assess treatments, outcomes and complications. IPCOR will improve patient care by identifying deficiencies in the service provided nationally. With this data, new resources could be more easily obtained for the prostate cancer services nationally.